Answers are grounded in this paper and cite their sources.
Splenectomy is a causal therapy option for adult primary immune thrombocytopenia (ITP), which achieves a long-term good therapeutic response (GTR) in 50-80% of patients. However, the frequency of postoperative complications, primarily bleeding, infection and thrombosis, is high and ranges up to 30%. Also, the risk of infections, as well as thrombosis (arterial and venous), is increased during the entire life of a splenectomized patient. In the era of new therapeutic drug modalities, such as rituximab and thrombopoietin receptor agonists (TPO-RA), splenectomy is less and less performed. In the available guidelines, there is no clear recommendation on the order of applying second-line therapeutic modalities. Namely, in the second therapeutic line, the 2019 American Society of Hematology guidelines, give preference to rituximab over splenectomy, and TPO-RA over rituximab, but do not give preference to TPO-RA over splenectomy. On the other hand, the 2019 International Working Group for ITP guidelines, do not give preference to any therapeutic modality, including splenectomy. Because of all the above, it is important to determine which patient has a high probability of achieving long-term GTR after splenectomy. Although the results from studies that have analyzed predictive factors for GTR after splenectomy are variable, patient age, preoperative platelet count, and platelet destruction in the spleen (determined by thrombocytokinetic testing) have been identified as predictive in most studies. Today, the use of splenectomy in ITP is considered a good therapeutic option for younger patients without comorbidities, who lead an active life and do not want frequent medical check-ups or are planning a pregnancy, as well as in patients with splenic platelet sequestration.
No takes yet. Share an insight, caveat, or question.
Mitrović et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: